JBCHEPHARM — J B Chemicals and Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- IN₹293.30bn
- IN₹293.36bn
- IN₹31.49bn
R2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,990 | 3,657 | 6,976 | 578 | 2,692 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,320 | 3,742 | 4,125 | 6,186 | 6,048 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 10,512 | 10,732 | 15,526 | 12,749 | 15,280 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,595 | 5,842 | 5,697 | 5,668 | 5,764 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 17,919 | 18,206 | 22,381 | 26,074 | 35,539 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,442 | 3,133 | 3,453 | 3,837 | 5,544 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,118 | 3,851 | 4,284 | 4,733 | 10,735 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 14,801 | 14,355 | 18,097 | 21,341 | 24,804 |
Total Liabilities & Shareholders' Equity | 17,919 | 18,206 | 22,381 | 26,074 | 35,539 |
Total Common Shares Outstanding |